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A B S T R A C T   
The aim of the present study was to investigate effects of the carotenoid-producing Bacillus indicus strain PD01 on 
intestinal barrier function and its ability to survive passage through the gastrointestinal tract and to assess 
systemic bioavailability of these carotenoids in vivo. As model for impaired barrier function, 16 early weaned 
piglets were randomly assigned to a control diet or control diet with PD01 for 23 days. In addition, 67 over-
weight/obese, otherwise healthy individuals were randomly assigned to groups receiving PD01 or placebo for 
6 weeks. PD01 survived passage through the gastrointestinal tract in piglets and human subjects and resulted in 
significant accumulation of PD01 derived carotenoids (methyl-glycosyl-apo-8′-lycopenoate and glycosyl-apo-8′- 
lycopene) in human plasma after 3- and 6-weeks supplementation versus baseline (0.044 and 0.076 vs 0 µM, 
respectively; p < 0.001). PD01 supplementation resulted in higher expression levels of occludin in the distal 
small intestine (1.38 ± 0.31 vs 0.59 ± 0.14; p = 0.044) and transepithelial electrical resistance in the mid colon 
(34.1 ± 3.01 vs 24.3 ± 1.13 Ω.cm2; p = 0.019) of early weaned piglets compared to control. In overweight/obese 
individuals with preserved barrier integrity, PD01 did not affect sugar excretion (p ≥ 0.104). In summary, PD01 
survived transit through the gastrointestinal tract, resulted in systemic carotenoid accumulation and improved 
compromised barrier function outcomes.   
1. Introduction 
The intestinal epithelial barrier plays an important role in the 
maintenance of intestinal homeostasis and in overall human health. It 
acts as a selective barrier allowing the absorption of substances such as 
water and essential nutrients, while preventing the translocation of 
luminal content and pathogens. In general, the barrier consists of a 
mucus layer, a single layer of epithelial cells sealed by junctional com-
plexes and underlying lamina propria. In addition to these components, 
other factors such as the mucosa-associated lymphoid tissue and the 
intestinal microbiota play a key role in maintaining the integrity and 
function of the intestinal barrier (Konig et al., 2016; Vancamelbeke & 
Vermeire, 2017). Defects in intestinal barrier functioning have been 
associated with the development and progression of various 
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gastrointestinal (GI) and metabolic diseases, including inflammatory 
bowel disease (IBD) and diabetes (Konig et al., 2016; Vancamelbeke & 
Vermeire, 2017). Therefore, treatments targeted at reducing intestinal 
permeability or preventing intestinal barrier dysfunction, could 
contribute to improve (GI) health. In this context, nutritional in-
terventions for instance with probiotic bacteria have been proposed. 
Probiotics may improve intestinal barrier function by stimulating the 
immune system, strengthening the physical barrier and by modulating 
the microbiota composition in favour of lactic acid bacteria (Bron et al., 
2017; Maldonado Galdeano, Cazorla, Lemme Dumit, Velez, & Perdigon, 
2019). Globally, lactic acid bacteria and Bifidobacterium spp. are the 
most consumed bacteria included in probiotic formulations. However, 
species belonging to other genera such as Enterococcus, Streptococcus, 
Bacillus, along with Saccharomyces spp., have also gained interest over 
the past years. Although not all Bacillus strains are considered safe for 
human consumption (Elshaghabee, Rokana, Gulhane, Sharma, & Pan-
war, 2017), probiotic properties including the prevention of pathogen 
colonization and reduced intestinal permeability have been shown for 
Bacillus spp. (Elshaghabee et al., 2017; Lopetuso, Scaldaferri, France-
schi, & Gasbarrini, 2016). Within this genus, the species Bacillus indicus 
has an extra attribute which is of interest to intestinal health. It has the 
ability to produce carotenoids which are lipophilic isoprenoid com-
pounds with well-known antioxidant, anti-apoptotic, and anti- 
inflammatory properties (Rodriguez-Concepcion et al., 2018). Further-
more, positive effects on microbiota composition have also been shown 
for carotenoids (Dingeo et al., 2020; Wiese et al., 2019). Therefore, in 
addition to the strain itself, the carotenoids that are produced may also 
play a role in improving barrier dysfunction via their antioxidant and 
anti-inflammatory effects and their ability to modulate the microbiota 
composition. Various animal studies have indeed shown beneficial ef-
fects of carotenoids on intestinal barrier function such as an increased 
expression of tight junction proteins and a reduction of intestinal 
epithelial damage (Hwang, Koh, Lee, Kim, & Lim, 2014; Singh et al., 
2016; Trivedi & Jena, 2015; Wang et al., 2019). 
The Bacillus indicus strain PD01 is a spore-forming bacterium origi-
nally isolated from human faeces from a healthy volunteer as HU19 
(Duc, Fraser, Tam, & Cutting, 2006), which fails to grow anaerobically. 
The bacterium naturally produces high levels of two glycosyl-apo- 
lycopene carotenoids (methyl-glycosyl-apo-8′-lycopenoate and 
glycosyl-apo-8′-lycopene) that do not degrade during passage through 
the stomach and are equally or even more bioaccessible and bioavailable 
than dietary carotenoids currently on the market (unpublished data 
from ProDigest, Ghent, Belgium). In addition to the potential probiotic 
properties of PD01 itself, the carotenoids released in the intestine may 
also result in local and systemic effects. Until now, data confirming these 
properties in vivo are lacking. Therefore, the aim of the present study is 
to investigate the effects of PD01 on intestinal barrier function in vivo. 
We chose to study this effect in early weaned piglets and in healthy yet 
overweight or obese subjects, as both early weaning stress and over-
weight have been associated with GI alterations, including a potential 
reduction in intestinal barrier integrity (Campbell, Crenshaw, & Polo, 
2013; Fasano, 2017; Salden et al., 2018). Additionally, we evaluated 
whether PD01 is able to survive transit through the GI tract in both 
piglets and humans, and whether PD01 is able to release systemically 
absorbable carotenoids that can be detected in human plasma. 
2. Methods 
2.1. Animal study 
The animal study was conducted in accordance with the ethical 
standards and recommendations for accommodation and care of labo-
ratory animals covered by the European Directive 2010/63/EU on the 
protection of animals used for scientific purposes and the Belgian royal 
decree KB29.05.13 on the use of animals for experimental studies. 
2.1.1. Animals and housing 
Sixteen healthy male and female piglets (Topics hybrid × Piétrain) 
were weaned at the age of 19 days (approx. average weight 6.5 kg), 
origin Stefaan Debaerdemaeker, Evergem, Belgium. The piglets, origi-
nated from four litters with four piglets/litter and were assigned to the 
pens according to litter of origin, sex and body weight (BW). Besides 
these criteria, the animals were allocated randomly to either one of the 
two treatments: basal control diet (CD) or basal control diet supple-
mented with Bacillus indicus strain PD01 at a concentration of 2 × 109 
spores/kg of diet (CD + PD01). The treatments lasted for a total of 
23 days, and were replicated in two pens of four piglets per pen (n = 8 
animals per treatment). Piglets were housed at the Laboratory for Ani-
mal Nutrition and Animal Product Quality of the Faculty of Bioscience 
Engineering from Ghent University (Ghent, Belgium). Four piglets were 
housed per pen (2.10 m2/pen) with full slatted floors, conventional 
ventilation scheme, starting ambient temperature at 30 ◦C and a 24L 
schedule till day (d)5 post-weaning. From d6 till d23, ambient temper-
ature was linearly adjusted to 28 ◦C with 18L:6D light schedule. No 
medications in feed or water were used. Health was recorded on a daily 
and individual basis. No animals or data points were excluded during the 
study because of signs of disease or animal deaths. 
2.1.2. Experimental diets and study product 
The basal control diet was formulated to meet or exceed the piglets’ 
requirements (adapted from Centraal Veevoeder Bureau, 1997) and was 
aimed to represent a human Western diet in terms of nutrients (Gunness 
et al., 2016). The diets were semi-synthetic, including minerals, and 
vitamins, but excluding supplementary organic acids, and Cu and Zn 
beyond animal requirements. The ingredient composition and calcu-
lated nutrient composition of the basal control diet is provided in 
Table s1. Feeds were prepared as mash. One batch was made and then 
split up to make the two experimental diets (CD and CD + PD01). Ba-
cillus indicus strain PD01 (MRM Health, Ghent, Belgium) was grown and 
lyophilized on a maltodextrin (Pineflow; Matsutani Chemical Industry, 
Hyogo, Japan) carrier with 89% spores per vegetative cells. Strain PD01, 
deposited at BCCM/LMG as Bacillus indicus PD01, was originally isolated 
and characterised by Duc et al. (2006) at Royal Holloway University of 
London (UK) from human faeces from a healthy volunteer (Bacillus 
indicus HU19 - NCIMB 41359). For the CD + PD01 diet, strain PD01 was 
added (2 × 109 spores/kg of diet) on top by premixing in a limited 
amount of basal diet, prior to complete mixing. All diets were fed ad 
libitum. No fasting period before sampling or sacrifice was included. 
Water was available ad libitum at all time. 
2.1.3. Animal follow-up 
The BW (kg) of the piglets was followed regularly: d0, d5, d14 and at 
the end of the trial (d23). For each period (d0-5, d5-14, d14-end and 
total period, d0-end) growth (g/d), feed intake (g/d) and feed to weight 
gain ratio (g/g) was recorded. All piglets were inspected two times a day 
for general health and presence of diarrhoea during the experimental 
period. The system used to score faecal consistency is provided in 
Table s2. To assess whether PD01 was detectable in the gastrointestinal 
tract of the piglets, at d14 and d23 a fresh non-contaminated faecal 
sample was collected from the rectum of each piglet. In addition, at d23 
samples from the mid colon were also collected post-mortem for the 
same purpose. 
2.1.4. Quantification of Bacillus indicus PD01 
The samples collected at d14 and d23 from the rectum and mid colon 
were weighted, and 0.5 g of sample was dissolved in sterile PBS. Serial 
dilutions of this faecal slurry (10− 1 to 10− 6) were plated in Luria Broth 
(LB) agar plates for colony counting (total cell count) upon incubation at 
37◦ C for 24 h. Because the PD01 strain of Bacillus indicus produces ca-
rotenoids, the colonies are easily identified by their bright yellow-to- 
orange appearance. For spore counting, the same samples were pas-
teurised at 65 ◦C for 30 min. Only spore-forming bacteria are able to 
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survive this treatment. Pasteurized samples were then plated in the same 
manner and colonies counted. Results are provided as colony forming 
units (CFU)/g of faecal sample. 
2.1.5. Collection of samples post-mortem 
All piglets were sacrificed on d23 postweaning. Just before eutha-
nasia, the weight of the piglets was registered. Piglets were euthanized 
by intra-peritoneal pentobarbital (90 mg/kg BW), followed by exsan-
guination. After piglets were killed, the abdomen was immediately 
opened to collect several intestinal sections: 50% and 90% of small in-
testinal length and of the mid colon. Samples were either used for his-
tomorphology, RNA extraction and quantitative (q)PCR, or for Ussing 
chambers. 
2.1.6. Histomorphology of intestinal segments 
Five cm segments of the 50% and 90% of small intestinal length were 
collected for histomorphology measurements (segments were flushed 
with saline and immersed in formalin). In brief, after fixation in neutral- 
buffered formalin, intestinal tissue samples were processed under stan-
dard conditions in an automatic tissue processor, embedded in paraffin 
wax and subsequently 5 μm slides were stained with haematoxylin-eosin 
(van Nevel, Decuypere, Dierick, & Molly, 2003). Villus length (from tip 
to base) and crypt depth (from base to opening) of all well-oriented villi 
and adjacent crypts were measured using a microscope equipped with a 
camera and computer with appropriate software (Olympus BX61 mi-
croscope and image analysis software, analySIS Pro, Olympus, Aartse-
laar, Belgium). Villus:crypt ratio was calculated as the mean value of the 
ratios of the obtained villus heights and adjacent crypt depths. 
2.1.7. Intestinal permeability and ion transport analysis using Ussing 
chambers 
Twenty cm segments of the 90% of small intestinal length and mid 
colon were collected for Ussing chamber measurements. Segments were 
flushed with saline, then cut along the mesenteric border, stripped of the 
muscle layers and mounted in modified Ussing Chambers (Andreas 
Mund Scientific Instruments, Simmerath, Germany) as flat sheets on a 
segment holder, with an exposed tissue area of 1.07 cm2 (Chen et al., 
2015). Immediately after mounting the tissues in the chambers, both 
half-chambers were filled with the Ringer’s buffer solution (pH 7.4) 
containing (in mmol/L): 115 NaCl, 25 NaHCO3, 0.4 NaH2PO4⋅H2O, 2.4 
Na2HPO4⋅2H2O, 5 KCl, 1.2 CaCl2⋅2H2O, MgCl2⋅6H2O and 12 D-glucose, 
however at the mucosal side of the epithelium the 12 mmol/L D-glucose 
in buffer was replaced by an equimolar amount of mannitol. Paracellular 
intestinal permeability of the tissue was assessed by the apparent 
permeability for FITC-dextran, 4 kDa (Sigma-Aldrich, Overijse, 
Belgium) in two chambers (Papp FD-4). Parameters of intestinal ion 
transport and tissue integrity in another two chambers. Two sets of Ag/ 
AgCl electrodes were connected to the half-chambers by 3 mmol/L KCl- 
agar bridges. One pair was used to record the potential differences be-
tween the half-chambers, while an external current ran through the 
other pair. After correction for solution resistance, the trans-epithelial 
potential difference was clamped to 0 mV by applying an external short- 
circuit current (Isc). Ion transport was evaluated by measuring the 
baseline Isc, and chloride- (Cl− ) stimulated secretion by the agonists 
carbachol (10 μM serosal-side; a Ca2+-mediated secretagogue; 
ΔIsccarbachol) and theophylline (5 mM, bilateral; a cAMP/cGMP medi-
ated secretagogue; ΔIsctheophylline) (Chen et al., 2015). Barrier function 
was determined by measuring the transepithelial electrical resistance 
(TEER). 
2.1.8. RNA extraction and qRT-PCR of tight junction protein genes 
Ten cm segments of the 50% and 90% of small intestinal length, and 
mid colon, were collected for real-time quantitative reverse- 
transcription (qRT)-PCR of two tight junction (TJ) protein genes: TJ 
protein 1 (Tjp1), encoding Zonula occludens 1 (ZO-1), and occludin 
(Ocln). For that, segments were flushed and mucosa was scraped, 
collected and stored in RNAlater® (Sigma-Aldrich) at − 80 ◦C until 
further RNA isolation. Total RNA was extracted by using the RNeasy 
Plus Mini Kit from Qiagen (Germantown, USA) and complementary (c) 
DNA was synthetized by using the High-Capacity cDNA Reverse Tran-
scription kit from Thermo Fisher Scientific (Dreieich, Germany) ac-
cording to the manufacturer’s instruction (0.5 µg of RNA was used for 
synthesis). All qPCRs were performed by using the StepOnePlus™ Real- 
Time PCR System (Applied Biosystems, Foster City, USA), the SensiMix 
SYBR Hi-ROX Kit from Bioline (London, UK) and by using 12.5 ng of 
template per reaction together with 250 nM of each primer (BioLegio, 
Nijmegen, the Netherlands) (all samples were tested in triplicate). 
Primer nucleotide sequences were as follows: Tjp1-Fw: 5′-ATCTCG-
GAAAAGTGCCAGGA-3′; Tjp1-Rev: 5′-CCCCTCAGAAACCCATACCA-3′; 
Ocln-Fw: 5′- CATGGCTGCCTTCTGCTTCATTGC-3′; Ocln-Rev: 5′- 
ACCATCACACCCAGGATAGCACTCA-3′. The hydroxymethylbilane syn-
thase (HMBS) gene was used as internal reference for normalization 
(HMBS-Fw: 5′-AGGATGGGCAACTCTACCTG-3′; HMBS-Rev: 5′- 
GATGGTGGCCTGCATAGTCT-3′) (Nygard, Jorgensen, Cirera, & Fred-
holm, 2007). Relative quantification (RQ) was performed according to 
the comparative 2− ΔΔCt method (Livak & Schmittgen, 2001) (for that a 
reference sample from the control diet group was randomly chosen for 
normalization) using the StepOne Software v2.3 (Applied Biosystems). 
2.2. Clinical study 
The clinical study was part of a larger project in which the effect of 
Bacillus indicus strain PD01 on cardiovascular health and microbial 
environment was investigated (Salden, 2017). The study was approved 
by the Medical Ethics Committee of the Maastricht University Medical 
Centre + (MUMC+) and conducted in full accordance with the princi-
ples of the Declaration of Helsinki of 1975 as amended in 2013 and with 
the Dutch Regulations on Medical Research involving Human Subjects 
(WMO, 1998). The study was performed at the MUMC+ from August 
2015 to December 2015. All participants gave written informed consent 
before participation. The trial has been registered in the Clinical Trials 
register (NCT02622425). 
2.2.1. Subjects 
Healthy, overweight or obese volunteers aged 18–70 years with a 
body mass index (BMI) between 25 and 35 kg/m2 were recruited by 
advertisement. Participants were excluded from the study when meeting 
one or more of the following exclusion criteria: any medical condition 
that might interfere with the study and might jeopardize the health 
status of the participant; smoking; high intake of fruits and vegetables 
(>75th percentile of dietary intake of fruits and vegetables in the gen-
eral Dutch population); abuse of alcohol (>20 alcoholic units / week) 
and drugs; absence of a stable body weight 3 months prior to the study 
(±3 kg); plans to lose weight or to follow a hypocaloric diet during the 
study period; use of medication/vitamin-, mineral- or antioxidant sup-
plements; consumption of pro-, pre- or synbiotics during study period 
and in the 30 days prior to start of the study; use of antibiotics 90 days 
prior to the study; pregnancy and lactation; history of any side effects 
towards the intake of pro-, pre-, synbiotic supplements or carotenoids. 
To assess the fruit and vegetable intake of the participants, a 3-day food 
record was completed prior to start of the study (during screening). 
During the study, the subjects were instructed to maintain their habitual 
diet. The sample size calculation was determined for the primary 
outcome of the original research protocol, i.e. lipid peroxidation, which 
is not included in this manuscript. Based on previous research (Visioli, 
Riso, Grande, Galli, & Porrini, 2003), it was calculated that a sample size 
of at least 60 subjects (i.e. 30 participants per intervention group) would 
be required. 
2.2.2. Study products 
Bacillus indicus strain PD01 (MRM Health, Ghent, Belgium) was 
grown and lyophilized on a maltodextrin (Pineflow; Matsutani Chemical 
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Industry, Hyogo, Japan) carrier with 89% spores per vegetative cells. 
The study products were provided as a powder in sachets. The PD01 
group received per day one sachet containing each 5 × 109 CFU PD01 
with maltodextrin (3 g) as carrier material. The amount of PD01 carot-
enoids present inside the spores of the clinical batch was determined 
after lipophilic extraction by spectrophotometry at 455 nm in 
dichloromethane (ε = 165 000 M− 1.cm− 1 and MW = 750 g.mol− 1). This 
amount was quantified as 2.81 µg per 109 CFU, resulting in a total of 
14.05 µg PD01 carotenoids per day. The placebo group received one 
sachet containing 3 g maltodextrin per day. Subjects were asked to stir 
the content of one sachet in 150 mL whole fat milk and ingest the so-
lution each morning, just before consuming breakfast, for a total of six 
weeks. 
2.2.3. Design and intervention 
This study was designed as a randomized, placebo-controlled, dou-
ble-blind, parallel-group study. Each subject underwent three test days. 
Participants were randomly assigned to one of the two intervention 
arms: PD01 or placebo (maltodextrin). An independent and blinded 
person generated the randomization list, using a computerized proced-
ure (http://randomizer.org). All participants and investigators 
remained blind to treatment until all analyses were completed. Partici-
pants were instructed to abstain from strenuous physical exercise, con-
sumption of alcohol and carotenoid-rich food products on the day prior 
to each test day. Assessments were performed in a quiet, temperature- 
controlled (20–24 ◦C) room. After an overnight fast, subjects handed 
in a faecal sample on the first test day. Then, anthropometric measure-
ments (height, body weight, waist-to-hip circumference) were per-
formed. Subsequently, venous blood samples were collected from an 
antecubital vein in the fore-arm. Then, subjects ingested a multi-sugar 
drink and collected full urine output for 24 h measurement. Finally, 
the subjects completed a questionnaire to assess the presence of GI 
symptoms, stool frequency and stool consistency. After completion of 
the baseline measurements, participants received the study product for 
the following six weeks. After three weeks of daily supplementation, the 
second test day was organized. Measurements were identical to the 
baseline measurements performed during the first test day, with the 
exception of the multi-sugar drink with 24 h urine collection, which was 
not performed after three weeks of intervention. After six weeks of daily 
administration of the study product, the third test day was organized, 
which was identical to the first test day. To assess compliance, partici-
pants were asked to collect the empty sachets and to return these at the 
last visit. 
2.2.4. Quantification of Bacillus indicus PD01 
Prior to analysis, faecal samples were thawed for 20 min and ho-
mogenized in sterile distilled water. Homogenized faecal samples were 
serially diluted in PBS buffer and total cell count and spore count were 
determined according to the methods described above. 
2.2.5. Bioavailability of bacterial carotenoids in plasma 
After collection, blood samples were kept in an ice-water bath and 
light exposure was avoided. Plasma was isolated by centrifugation 
(10 min, 1400 g, 4 ◦C) within 2 h following collection and stored at 
− 80 ◦C until further analysis. Carotenoids were extracted by the Bligh 
and Dyer method (Bligh & Dyer, 1959). Then, an enzymatic step, ac-
cording to Breithaupt, was carried out to hydrolyse esterified caroten-
oids (Breithaupt, 2000). Carotenoids were quantified by reverse-phase 
HPLC as described by Gleize, Steib, Andre, and Reboul (2012) using an 
HP1100 Agilent system equipped with a 150 × 4.6 mm i.d. C30 column 
(YMC, Kyoto, Japan) set at 35 ◦C. Mobile phase consisted of a gradient of 
methanol (A), methyl tert-butyl ether (B) and water (C) and the flow rate 
was 1 mL/min. The gradient profile of the mobile phase (A:B:C) was set 
at 96:2:2 and changed linearly to 18:80:2 in 27 min, and then the mobile 
phase was changed back to 96:2:2 from 31 to 35 min. The carotenoids 
were identified at 460 nm based on retention time and UV–Visible 
spectra (for PD01 carotenoids spectra, see Perez-Fons et al. (2011)). The 
absorption spectra of each standard were measured between 300 and 
550 nm in the mobile phase to cross-check the identification of sample 
molecules. Quantification was performed comparing peak area with 
standard calibration curves. Lutein, β-carotene and lycopene standards 
were purchased from Carotenature (Münsingen, Switzerland) and PD01 
carotenoids standard was purified from PD01 spores as detailed by Sy, 
Dangles, Borel, and Caris-Veyrat (2015). 
2.2.6. Gastrointestinal permeability 
Gastrointestinal permeability was assessed by using a validated 
multi-sugar test (van Wijck, van Eijk, Buurman, Dejong, & Lenaerts, 
2011; van Wijck et al., 2013), measuring the urinary excretion of 
ingested sugar probes reflecting permeability of four segments of the GI 
tract. The method of measurement has been described previously by 
Mujagic et al. (2014). Urinary sugar probes were measured by HPLC-MS 
as previously described (van Wijck et al., 2011; van Wijck et al., 2013). 
2.2.7. Gastrointestinal tolerance 
The occurrence of GI symptoms was assessed using the validated 
gastrointestinal symptom rating scale (GSRS), consisting of 15 items 
combined into five symptom clusters describing reflux, abdominal pain, 
indigestion, diarrhoea, and constipation (Svedlund, Sjodin, & Dotevall, 
1988). In the seven-point graded Likert-type GSRS, a score of 1 repre-
sents absence of troublesome symptoms and a score of 7 represents very 
troublesome symptoms. Defecation frequency and stool consistency 
were assessed by using the Bristol Stool Form Scale Chart (Riegler & 
Esposito, 2001). 
2.3. Statistical analyses 
Normality of the data was evaluated by using the Shapiro-Wilk test 
and statistical tests were applied accordingly. For the animal study, 
statistically significant differences between the control and test diet 
were assessed by unpaired, two-tailed Student’s t-tests for normally 
distributed data and Mann-Whitney U tests for data that were not nor-
mally distributed. Differences between two time points were assessed by 
two-tailed paired Student’s t-tests. 
For the clinical study, baseline differences between intervention 
groups were tested using unpaired, two-tailed Student’s t-tests, Mann- 
Whitney U tests or Chi-square tests when appropriate. To compare the 
presence of PD01 in faeces and bacterial carotenoids in plasma between 
baseline samples and samples collected after three and six weeks of 
supplementation, per protocol analyses were performed based on all 
participants that actually consumed the study product, by using the 
Friedman test with post-hoc Wilcoxon Singed Rank test. For GI perme-
ability, GI tolerance, stool consistency and stool frequency per protocol 
analyses were performed based on all participants that completed the 
study protocol. For these outcomes, differences between intervention 
groups (PD01 or placebo) were assessed using linear mixed models with 
intervention group (placebo and PD01), time (baseline, three weeks and 
six weeks) and intervention group*time as fixed factors, where an un-
structured covariance structure was used for repeated measures. The 
linear mixed model accounts for the correlation between repeated 
measures and missing data, where a likelihood approach was used 
assuming data missing at random and can be used for data showing 
limited skewedness providing a sufficient sample size. Final conclusions 
were confirmed in a sensitivity analysis using log transformed data. 
All statistical analyses were performed using IBM SPSS Statistics for 
Windows (version 25.0, Armonk, NY, USA). Data analysed by para-
metric tests are presented as mean ± SEM or medians with interquartile 
ranges for data analysed by non-parametric tests. Two-sided p- 
values ≤ 0.05 are considered significant. Correction for multiple testing 
was performed by Bonferroni correction based on a correction for 
multiple time points. 
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3. Results 
3.1. Animal study 
3.1.1. Faecal quantification of Bacillus indicus PD01 
Faecal samples from the rectum and mid colon of early weaned 
piglets were collected at day 14 (only rectum) and day 23 (rectum and 
mid colon). The number of total bacterial cells and spores detected in the 
rectum was high and did not increase significantly from day 14 to day 23 
(Table 1). In the faeces collected post-mortem from the mid colon, the 
number of total cells and spores was also high (1.83 × 106 and 
1.38 × 106 CFU/g faeces, respectively). This indicates that PD01 was 
present in a viable form in the gut of the animals that received PD01. 
3.1.2. Intestinal barrier function 
PD01 supplementation did improve barrier function in early weaned 
piglets (Table 2). Both in the distal small intestine and mid colon, PD01 
supplementation resulted in higher TEER values (p = 0.070 and 
p = 0.019 at 90% of small intestinal length and mid colon, respectively), 
although this effect was only significant in the mid colon. To investigate 
whether the positive effects observed could be attributed to changes in 
the expression of TJ proteins, we have measured the expression of Tjp1 
and Ocln in the small intestine and mid colon of the piglets. A signifi-
cantly higher Ocln gene expression in the distal small intestine was 
observed for the group fed PD01 when compared to the control diet 
(Fig. 1). 
3.1.3. Gastrointestinal tolerance 
Although statistical analyses could not be performed on indices per 
pen, the average pen data indicate that supplementation of the piglet’s 
diet with Bacillus indicus PD01 did not have a major impact on animal 
performance in terms of total body weight, daily growth or feed intake 
(Table s3). The mean faecal score was also similar between the two diets. 
No diarrhoea was recorded for any of the groups. Also no differences 
were observed in histomorphology in terms of crypt depth and villus 
height, both at 50% and 90% small intestinal length (Table 3; Figure s1). 
3.2. Clinical study 
3.2.1. Study subjects 
For the clinical trial, 67 healthy overweight or obese volunteers were 
enrolled of which 62 completed the entire study protocol (Fig. 2). One 
randomised participant did not start the study for a personal reason. 
Four participants dropped out during the intervention period: one due to 
the need for antibiotic treatment being unrelated to the current study, 
another for unspecified, private reasons, and the two remaining partic-
ipants experienced mild GI complaints. These complaints were present 
already at the start of the study and were not associated to PD01 intake. 
From these participants only baseline characteristics were available. 
Baseline characteristics are presented in Table 4. From the total of 67 
randomized subjects, 33 participants in the placebo group and 29 par-
ticipants in the PD01 group completed the study protocol. 
3.2.2. Quantification of Bacillus indicus PD01 
In the group of subjects receiving placebo, PD01 was not detected in 
any of the faecal samples. In the PD01 group, PD01 was not detected in 
any of the faecal samples at baseline, but was found in faecal samples of 
all 29 subjects after three weeks of supplementation and was present in 
all of the subjects that consumed PD01 during the complete study period 
(n = 27) after six weeks. As shown in Table 5, PD01 total cells and spores 
were significantly increased both after three weeks and six weeks sup-
plementation, compared to baseline (all p < 0.001). No significant dif-
ferences could be observed between three and six weeks of 
supplementation both for total cells and spores. The total amount of 
viable PD01 cells in human faeces after six weeks of PD01 supplemen-
tation was quantified as 2.26 × 107 CFU/g, of which 3.43 × 106 CFU/g 
are PD01 spores. Thus, although administered as spores, PD01 was 
mainly present in the faeces as vegetative cells (1.99 × 107 CFU/g; 73% 
of total counts), indicating effective germination under intestinal 
conditions. 
3.2.3. Bioavailability of PD01 carotenoids in plasma 
In fasted plasma, PD01 carotenoids were detected in samples of all 
subjects after three weeks (0.044 µM) and six weeks (0.076 µM) of PD01 
supplementation, but not in the baseline samples. The total plasma 
concentration of PD01 carotenoids were significantly increased after 
Table 1 
PD01 total cells and spores (CFU/g) in the gastrointestinal tract of piglets 
at day 14 and at the end of the study in the CD þ PD01 group. Total cell 
count was performed by plating serial dilutions of collected samples in LB agar 
plates. Spore count was performed in the same manner and on the same samples 
after pasteurization at 65◦ C. Vegetative cells are calculated as the difference 
between total cell count and spore count. Average CFU/g of fecal sample are 
presented, and percentage from total cells were calculated for both spores and 
vegetative cells. All values are presented as mean ± SEM.   
Faeces (rectum)  Faeces (mid- 
colon)  
Day 14 
(n = 6) 
Day 23 




(n = 8) 
Total cells 1.52E+06 ± 3.08 
E+05 
2.62 
E+06 ± 6.46 
E+05  
0.218 1.83 
E+06 ± 8.29 
E+05 
Spores 1.45 E+06 ± 4.24 
E+05 
1.86 
E+06 ± 3.64 
E+05  
0.541 1.38 




96% 71%  75% 
Vegetative 
cells 
6.33 E+04 ± 2.85 
E+05 
7.63 
E+05 ± 3.90 
E+05  
0.331 4.48 




4% 29%  25% 
Differences between day 14 and day 23 were tested with a paired student’s t-test. 
CD: basal control diet. 
Table 2 
Effect of control (CD) and test diets (CD þ PD01) on intestinal permeability 
and electrophysiological parameters as determined in the distal small in-
testine and mid colon sections of piglets by using Ussing chambers. All 
values are presented as mean ± SEM (n = 8/group/segment).    
CD CD þ PD01 P- 
value 
– SI length (m) 9.88 ± 0.35 10.5 ± 0.37  0.244 
90% of small 
intestinal 
length 
Papp FD-4 (10¡7 
cm/s) 
13.4 ± 2.62 9.89 ± 1.91  0.303 
TEER (Ω.cm2) 36.4 ± 2.47 46.2 ± 4.30  0.070 
ΔIsccarbachol (µA/ 
cm2) 
34.8 ± 11.11 35.8 ± 10.0  0.951 
ΔIsctheophylline 
(µA/cm2) 
30.6 ± 7.38 17.4 ± 2.28  0.100 
Mid colon Papp FD-4 (10¡7 
cm/s) 
23.6 ± 3.58 16.9 ± 3.37  0.194 
TEER (Ω.cm2) 24.3 ± 1.13 34.1 ± 3.01  0.019 
ΔIsccarbachol (µA/ 
cm2) 
63.2 ± 9.54 71.9 ± 9.78  0.538 
ΔIsctheophylline 
(µA/cm2) 
53.1 ± 9.18 46.1 ± 6.12  0.533 
Differences between control and test diet were tested with an unpaired student’s 
t-test. CD: basal control diet; SI: small intestine (90% length); Papp FD-4: 
apparent permeability for FITC-Dextran 4 kDa; TEER: transepithelial electrical 
resistance of tissue; ΔIsccarbachol and ΔIsctheophylline: changes in short-circuit 
current upon stimulation with chloride secretagogues carbachol and theophyl-
line, respectively. 
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three weeks and continued to increase during the six weeks of daily 
supplementation (all p ≤ 0.027, Table 6). The PD01 carotenoids detec-
ted in plasma were methyl-glycosyl-apo-8′-lycopenoate and glycosyl- 
apo-8′-lycopene, with methyl-glycosyl-apo-8′-lycopenoate making up 
74.6% and 85.3% of the total concentration after 3 and 6 weeks, 
respectively. Bacillus indicus PD01 supplementation did not induce sig-
nificant changes in the plasma content of lutein, β-carotene or lycopene 
during the study period (all p ≥ 0.618, Table 6). The presence of (bac-
terial) carotenoids in plasma samples of subjects from the placebo group 
was not assessed, as bacterial carotenoids proved undetectable in the 
baseline sample of the subjects. Representative chromatograms of ca-
rotenoids found in plasma before and after supplementation are shown 
in Fig. 3. 
3.2.4. Gastrointestinal permeability 
The GI permeability results, as determined by the multi-sugar test, 
are presented in Table 7. Neither did the excretion of sugars indicative 
for small intestinal (p = 0.842) or whole gut permeability (p = 0.266) 
differ after six weeks PD01 supplementation nor did the changes in sugar 
excretion reflecting gastroduodenal (p = 0.131) or colonic (p = 0.104) 
permeability reach statistical significance after six weeks PD01 supple-
mentation compared to placebo. 
3.2.5. Gastrointestinal tolerance 
GI tolerance was assessed by GSRS subdimension scores at every test 
day. As shown in Figure s2, the scores for indigestion decreased in the 
PD01 treatment group after six weeks of supplementation (uncorrected 
p = 0.045), but this reduction did not remain statistically significant 
after correction for multiple testing (p = 0.135). For the other gastro-
intestinal symptom scores and time points, also no significant changes 
were observed after PD01 supplementation compared to placebo (all 
p ≥ 0.183, Figure s2), indicating that PD01 was well tolerated. Neither 
PD01 nor placebo did affect stool frequency or consistency throughout 
the study period (data not shown). 
4. Discussion 
This is the first in vivo study evaluating the effect of a carotenoid- 
producing Bacillus strain on intestinal barrier function as well as its in-
testinal fate and ability to release systemically absorbable carotenoids in 
a combined animal and human approach. We have shown that Bacillus 
indicus strain PD01 survives transit through the GI tract in both piglets 
and human subjects and was able to release carotenoids in situ. Sup-
plementation with PD01 resulted in a significant improvement in out-
comes of intestinal barrier function in early weaned piglets, but did not 
significantly affect intestinal barrier permeability in healthy overweight 
or obese human subjects. Repeated intake of PD01 did not result in any 
adverse effects, not in early weaned piglets nor in human subjects. 
In both piglets and humans, PD01 survived passage through the GI 
tract and was able to germinate into vegetative cells under intestinal 
conditions, although germination seems to be more efficient in humans 
based on the percentage of vegetative cells present in the faeces after 
supplementation. This difference in results between the piglets and 
humans may be due to interspecies differences in GI physiology, in 
particular gastric emptying (Hatton, Yadav, Basit, & Merchant, 2015; 
Suenderhauf & Parrott, 2013). Furthermore, we have shown that in 
humans, daily PD01 supplementation over a period of six weeks led to a 
significant accumulation of PD01 carotenoids in plasma. These carot-
enoids, methyl-glycosyl-apo-8′-lycopenoate and glycosyl-apo-8′-lyco-
pene, are normally not present in the diet. In plasma, no changes in 
concentrations of the three main dietary carotenoids (i.e. lutein, 
β-carotene and lycopene) were observed, indicating that subjects did not 
change their dietary carotenoid intake during the study and these novel 
PD01 carotenoids do not interfere with the absorption and transport of 
other carotenoids. Plasma concentrations of the PD01 carotenoids were 
slightly lower in comparison with those of the dietary carotenoids. This 
is not surprising as in general the average intake of these carotenoids 
(10 mg/day) is of a much higher magnitude than the calculated daily 
dose of 14.05 µg PD01 carotenoids (Sluijs et al., 2015). Still, the fact that 
bacterial carotenoid levels reached similar order of magnitude levels in 
plasma upon a six-week intake, despite the much lower intake levels, 
further suggests that PD01 is capable of local production of high 
amounts of bacterial carotenoids in the intestine, in combination with 
high bioavailability of the released carotenoids. 
In early weaned piglets, we observed an improvement in intestinal 
barrier function in animals fed a diet supplemented with Bacillus indicus 
strain PD01. Others did previously show with this model that the pro-
biotic strain Lactobacillus frumenti was able to promote intestinal barrier 
function, via increased expression levels of the TJ proteins ZO-1, Ocln 
Fig. 1. Changes in tight junction protein gene expression in the (A) mid small intestine, (B) distal small intestine, and (C) mid colon of piglets upon 
supplementation of diet with PD01. Means and standard errors are shown (n = 8 animals/group/segment). Mid and distal small intestine correspond to the 50% 
and 90% small intestinal length tissues, respectively. The expression of tight junction protein 1 (Tjp1) and occludin (Ocln) were normalized to hydroxymethylbilane 
synthase (HMBS). Differences between control and test diet were tested with an unpaired student’s t-test. For 90% SI length, TJP1 expression was tested with a Mann- 
Whitney U test. 
Table 3 
Effect of control (CD) and test diets (CD þ PD01) on histomorphology of 
small intestinal mucosa. Data are presented as mean ± SEM (n = 8/group/ 
segment).    
CD CD þ PD01 P-value 
50% SI Crypt depth (µm) 143 ± 2.51 145 ± 4.59  0.710 
Villus height (µm) 358 ± 20.1 331 ± 27.3  0.435 
Villus:crypt ratio 2.56 ± 0.13 2.31 ± 0.13  0.191 
90% SI Crypt depth (µm) 139 ± 7.02 136 ± 4.92  0.764 
Villus height (µm) 305 ± 18.1 328 ± 26.5  0.495 
Villus:crypt ratio 2.25 ± 0.12 2.44 ± 0.13  0.205 
Differences between control and test diet were tested with an unpaired student’s 
t-test. For 90% SI length, the villus:crypt ratio was tested with a Mann-Whitney 
U test. CD: basal control diet; SI: small intestine (50% and 90% length). 
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and Claudin-1 (Hu et al., 2018). In addition to any potential effects of the 
Bacillus indicus strain PD01 itself, the carotenoids released in the intes-
tine following PD01 supplementation may have been responsible or 
could have contributed to the observed improvement in barrier function. 
To date, in different mouse models associated with intestinal barrier 
disruption, treatment with the carotenoids β-carotene and lycopene 
resulted in an improvement in markers for intestinal barrier integrity 
and for colonic damage (Singh et al., 2016; Trivedi & Jena, 2015; Wang 
et al., 2019). In the current study, PD01 supplementation resulted in 
higher expression levels of Ocln in the distal small intestine of the 
piglets. These increased expression levels were not accompanied by a 
significant change in TEER or transcellular permeability in the small 
intestine, although a slight improvement in both outcomes could be 
observed. In the mid colon, PD01 supplementation resulted in a signif-
icantly increased TEER, while TJ gene expression levels of Tjp1 and Ocln 
were not affected. These findings do not exclude effects on protein 
levels, but can also be due to other tight junction or adherens junction 
related factors (Ulluwishewa et al., 2011). In future studies, additional 
analyses on the expression of junctional proteins and activity of sig-
nalling cascades will contribute to further insight in underlying 
mechanisms. 
In our population of overweight or obese subjects, no significant 
effects on barrier function were observed as a result of PD01 intake. 
Intestinal barrier function was assessed by the use of a multi-sugar test 
measuring urinary recovery of sugars indicative of gastroduodenal, 
small intestinal, colonic and whole gut permeability. This method has 
been widely used and validated for non-invasive measurement of GI 
permeability in human subjects (van Wijck et al., 2013). Although 
overweight and obesity have been associated with an impaired barrier 
function, a recent study in morbidly obese patients that assessed intes-
tinal permeability using the same sugar test showed that only gastro-
duodenal permeability was significantly increased in obese subjects, 
while small intestinal and colonic permeability were not increased when 
compared to healthy lean subjects (Wilbrink et al., 2019). These recent 
results indicate that in overweight/obese subjects who are otherwise 
healthy, in contrast to previously expected, intestinal permeability is not 
increased. Therefore, this group may not have been the most suitable 
study population to study effects on this outcome. So far, data from 
Fig. 2. CONSORT flow diagram.  
Table 4 
Baseline characteristics of the clinical study participants. Values are pre-
sented as medians [Q1; Q3] or numbers.   
Total 
population 
(n = 67) 
Placebo 
(n = 34) 
PD01 
(n = 33) 
P- 
value 





Sex, M/F 29/38 12/22 17/16  0.180 












Differences in Age and BMI between placebo and PD01 were tested with a Mann- 
Whitney U test. Differences in WHR between placebo and PD01 were tested with 
an unpaired student’s t-test. Differences in gender between placebo and PD01 
were tested with a Chi-square test. M: male; F: female; WHR: waist-to-hip-ratio; 
BMI: body mass index. 
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human intervention trials investigating the effect of probiotics on in-
testinal barrier function in overweight or obese subjects are scarce and 
show varying results (Krumbeck et al., 2018; Leber et al., 2012) while 
data on carotenoids are still lacking. For example, daily supplementation 
with Lactobacillus casei Shirota for three months did not have any sig-
nificant effects on intestinal permeability (Leber et al., 2012), while the 
intestinal barrier was found to be significantly improved after three 
weeks of supplementation with Bifidobacterium adolescentis IVS-1 or 
Bifidobacterium lactis BB-12 (Krumbeck et al., 2018). Altogether, the 
results from the piglet and human studies show that while supplemen-
tation with PD01 was not able to induce any changes in intestinal barrier 
permeability in a healthy overweight/obese population, it was able to do 
so in an animal model of impaired barrier function. Therefore, further 
investigations regarding the effect of PD01 supplementation in specific 
patient groups with a more clearly compromised barrier integrity, 
particularly those in which immune-mediated barrier disruption is 
likely, are worthwhile. Use of a stressor that is able to induce a transient 
disruption of intestinal barrier function could also provide additional 
insight. 
As this was one of the first studies performed in vivo with this 
particular Bacillus strain (PD01), animal growth performance and GI 
tolerance were assessed during the intervention periods. In animals, no 
changes in total body weight, daily growth, feed intake or faecal scores 
were observed as a result of PD01 feeding. In human subjects, gastro-
intestinal symptom scores, stool frequency and stool consistency were 
also not significantly affected by the intake of PD01. These results show 
that PD01 did not result in any adverse effects and was well tolerated in 
early weaned piglets and in healthy overweight/obese subjects. This is 
in line with data from a previous study assessing the safety profile of a 
similar strain (HU36) in guinea pigs and rabbits (Hong et al., 2008). 
Furthermore, toxicity and safety trials in mice and healthy lean and 
obese human subjects with supplementation periods of up to 90 days 
showed that repeated intake of Bacillus indicus strain PD01 was not 
associated with any adverse effects (unpublished data from ProDigest, 
Ghent, Belgium). 
Some potential shortcomings of our study should be mentioned. 
First, the diet of the participants was not strictly controlled in the clinical 
study. We instructed participants to maintain their habitual dietary 
intake throughout the study period, as we aimed to assess the effects of 
PD01 as supplement to their habitual diet, which is in line with future 
applications. Based on the unchanged plasma concentrations of lutein, 
lycopene, and β-carotene it can be assumed that the habitual diet was 
indeed maintained. Second, the study population chosen for the current 
study was relatively healthy, because PD01 is a new product which so far 
has only been tested in healthy human volunteers. Third, the required 
sample size of the human intervention study was not calculated based on 
an improvement in intestinal permeability, as this was not the primary 
outcome of the original study protocol. Therefore, this study might have 
lacked sufficient power to confirm the effects on intestinal barrier 
function observed in animal models. Fourth, statistical analyses could 
not be performed on piglet performance indices, as these were based on 
data per pen. Last, the barrier function results in the animal study were 
in some cases borderline significant or a trend toward significance, 
indicating that the results have to be interpreted with caution. 
Table 5 
PD01 total cells and spores (CFU/g) in faecal samples of the clinical study participants at baseline, after 3 weeks and after 6 weeks supplementation with 
PD01 (n ¼ 27). All values are presented as medians [Q1; Q3].   
Baseline 3 weeks 6 weeks P1 P2 P3 P4 
Total cells 0 [0; 0] † 2.50 E+07 
[1.11 E+07; 3.98 E+07] 
2.26 E+07 
[1.06 E+07; 4.19 E+07]  
<0.001  <0.001  <0.001  0.939 
Spores  
Percentage of total 
0 [0; 0] 
0 
5.77 E+06 




[1.85 E+06; 1.06 E+07] 
27 
[7; 39]  
<0.001  <0.001  <0.001  0.117 
Vegetative cells  
Percentage of total 
0 [0; 0] 
0 
1.70 E+07 




[5.65 E+06; 2.93 E+07] 
73 
[61; 93]  
<0.001  <0.001  <0.001  >0.999 
Differences between baseline and 3 weeks and 6 weeks supplementation were tested with Friedman test with post hoc Wilcoxon signed rank test. Correction for 
multiple testing was performed by Bonferroni correction. P1 represent the p values for the overall difference between the three time points tested with the Friedman 
test. P2 represent the adjusted p values for the analysis of baseline vs. 3 weeks of intervention. P3 represent the adjusted p values for the analysis of baseline vs. 6 weeks 
of intervention. P4 represent the adjusted p values for the analysis of 3 weeks vs. 6 weeks of intervention. † Values that could not be detected, depicted here as 0 (all such 
values). 
Table 6 
Carotenoid concentrations (µM) in fasted plasma of the clinical study participants at baseline, after 3 weeks and after 6 weeks supplementation with PD01 
(n ¼ 27). All values are presented as medians [Q1; Q3].   
Baseline 3 weeks 6 weeks P1 P2 P3 P4 
PD01 carotenoids 0 [0; 0] † 0.044 
[0.016; 0.073] $ 
0.076 
[0.042; 0.14] ¥  






[0.091; 0.22]  






[0.17; 0.44]  






[0.087; 0.28]  
0.936  –  –  – 
Differences between baseline and 3 weeks and 6 weeks supplementation were tested with Friedman test with post hoc Wilcoxon signed rank test. Correction for 
multiple testing was performed by Bonferroni correction. P1 represent the p values for the overall difference between the three time points tested with the Friedman 
test. P2 represent the adjusted p values for the analysis of baseline vs. 3 weeks of intervention. P3 represent the adjusted p values for the analysis of baseline vs. 6 weeks 
of intervention. P4 represent the adjusted p values for the analysis of 3 weeks vs. 6 weeks of intervention. In case post hoc Wilcoxon signed rank test was not applicable, 
no p values are reported. † Values that could not be detected, depicted here as 0. $ Sum of methyl-1-glycosyl-3,4-dehydro-apo-8′-lycopenoate (74.6%) and 1-glycosyl- 
3,4-dehydro-apo-8′-lycopene (25.4%), non-esterified carotenoids of PD01. ¥ Sum of methyl-1-glycosyl-3,4-dehydro-apo-8′-lycopenoate (85.3%) and 1-glycosyl-3,4- 
dehydro-apo-8′-lycopene (14.7%), non-esterified carotenoids of PD01. 
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Fig. 3. Representative chromato-
grams of carotenoid standards (A) 
and carotenoid profiles in fasted 
plasma at baseline (B) and after 
6 weeks supplementation with PD01 
(C). Carotenoids were analyzed by 
reverse-phase HPLC on a HP1100 Agi-
lent system using a YMC C30 column. 
Free forms of carotenoid were detected 
at 460 nm and identified by retention 
time compared with pure standards. The 
absorption spectra of each standard 
were measured between 300 and 
550 nm in the mobile phase to cross- 
check the identification of sample mol-
ecules. 1: Lutein, 2: Methyl-glycosyl- 
apo-8′-lycopenoate (free form of orange 
bacterial carotenoid produced by PD01 
strain), 3: Glycosyl-apo-8′-lycopene (free 
form of yellow bacterial carotenoid 
produced by PD01 strain), 4: β-Carotene, 
5: Lycopene.   
Table 7 
Permeability test: sugar excretion (µmol) and ratios of excreted sugars as measured in urine (0–5, 5–24 and 0–24 h fractions) of the clinical study par-
ticipants at baseline and after 6 weeks supplementation (n ¼ 62). All values are presented as mean ± SEM.   
Placebo PD01 P 
Baseline 6 weeks Baseline 6 weeks 
0–5 h sucrose 8.92 ± 1.76 12.0 ± 3.22 11.4 ± 2.14 8.46 ± 2.04  0.131 
0–5 h L/R ratio 0.042 ± 0.010 0.032 ± 0.003 0.049 ± 0.010 0.042 ± 0.008  0.842 
5–24 h S/E ratio 0.013 ± 0.001 0.018 ± 0.004 0.051 ± 0.025 0.017 ± 0.002  0.104 
0–24 h S/E ratio 0.014 ± 0.001 0.014 ± 0.002 0.031 ± 0.014 0.016 ± 0.002  0.266 
Differences between placebo and PD01 were tested with an unstructured linear mixed model with correction for baseline values. L/R: lactulose/l-rhamnose; S/E: 
sucralose/erythritol. 
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In conclusion, this study provides the first evidence that PD01 sur-
vives transit through the GI tract, is able to germinate and is able to 
release bacterial carotenoids, which are absorbed and detected in 
human blood plasma. Furthermore, PD01 supplementation resulted in 
improved barrier function outcomes in an animal model of disturbed 
intestinal barrier in early weaned piglets. While no significant effects on 
barrier function were found in an overweight/obese, but otherwise 
healthy population, these results warrant further research in specific 
target populations to investigate the specific bioactivities of PD01 in the 
intestine and possibly also on systemic parameters. 
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